Skip to main content

Advertisement

Log in

A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working group

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

S-l is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoro-pyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal toxicity which is widely used in Japan against advanced gastric, head and neck cancers. We investigated its clinical efficacy against metastatic breast cancer.

Methods

A non-blind phase II study was carried out to evaluate the efficacy and toxicity in metastatic breast cancer patients. Patients with measurable metastasis foci (n = 111) were enrolled, and 108 patients were regarded as eligible. S-l was administered orally at a standard dose of 80 mg/m2/day b.i.d. One course consisted of 28 consecutive days of administration followed by a 14-day rest, and courses were repeated up to six times.

Results

Among the eligible patients, 10 had a complete response and 35 had a partial response, with an overall response rate (CRplus PR) of 41.7% (95% confidence interval: CI, 32.3–51.5%). The incidences of toxicity (≧ grade 3) were neutropenia 9.1%, anemia 0.9%, anorexia 3.6%, stomatitis 1.8%, nausea/vomiting 1.8%, diarrhea 0.9%, and fatigue 2.7%, however no treatment-related deaths were observed. The median survival time was 872 days (95% CI, 572-1,110 days). There was no difference in response rate or toxicity between the under 65-year-old group and the older group.

Conclusion

S-l was demonstrated to have high efficacy with low gastrointestinal toxicity even in older patients and will be a promising new chemotherapy drug for metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

CI:

Confidence interval

CR:

Complete response

CVI:

Continuous venous infusion

DPD:

Dihydropyrimidine dehydrogenase

DIF:

DPD-inhibitory fluoropyrimidine

FT:

Tegafur

5-FU:

5-Fluorouracil

MST:

Median survival time

NC:

No change

ND:

Not detected

OPRT:

Orotate phosphoribosyl transferase

PD:

Progressive disease

PR:

Partial response

QOL:

Quality of life

RR:

Response ratio

References

  1. Piccart MJ, Awada A, Hamilton, A: Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. 35th ASCO Educational Book, pp526–539, 1999.

  2. Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellmann S, Henderson IC, Kinne DW eds, Breast Diseases, 2nd ed, JB Lippincott Co, Philadelphia, pp604–665, 1991.

    Google Scholar 

  3. Stadtmauer EA, O’Neil A, Goldstein LJ, Crilley P, Mangan KF, Ingle JN, Lazarus HM, Erban J, Sickles C, Glick JH: Phase II randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotorexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia intergroup study (PBT-1). 35thProc Am Soc Clin Oncol 18:#1a, 1999.

    Google Scholar 

  4. Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.Annal Oncol 7:807–813, 1996.

    CAS  Google Scholar 

  5. Meta-analysis group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectalcancer. J Clin Oncol 16:301–308, 1998.

    Google Scholar 

  6. Chlebowski RT, Weiner JM, Luce J, Hestorff R, Lang JE, Reynolds R, Godfrey T, Ryden VM, Bateman JR: Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.Cancer Res 41:4399–4403, 1981.

    PubMed  CAS  Google Scholar 

  7. Au JL, Sadee W: The pharmacology of ftorafur (R, S-1-(tetrahydro2-furanyl)-5-fluorouracil). In: Carter SK, Sakurai Y, Umezawa H eds, New drugs in cancer chemotherapy, Springer-Verlag, New York, pp100–114, 1981.

    Google Scholar 

  8. Ansfield FJ, Kallas GJ, Singson JP: Phase I-II studies of oraltegafur (ftorafur).J Clin Oncol 1:107–110, 1983.

    PubMed  CAS  Google Scholar 

  9. Kajanti MJ, Pyrhonen S, Maiche AG: An oral tegafur in the treatment of metastatic breast cancer, a phase II study.EurJ Cancer 29A:863–866, 1993.

    Article  Google Scholar 

  10. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study.Cancer Chemother Pharmacol 22:333–338, 1988.

    Article  PubMed  CAS  Google Scholar 

  11. Taguchi T, Terasawa T, Abe O, Yoshida Y, Tominaga T, Ogawa NA: Comparative study between 5’-DFUR and tegafur in recurrent breast cancer.Jpn J Cancer Chemoth 12:2052–2060, 1985 (in Japanese with English abstract).

    CAS  Google Scholar 

  12. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.EurJ Cancer 34:1274–1281, 1998.

    Article  CAS  Google Scholar 

  13. Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver.J Biol Chem 267:17102–17109, 1992.

    PubMed  CAS  Google Scholar 

  14. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase inhibition.Oncology 13 (Suppl. 3): 17–21, 1999.

    PubMed  CAS  Google Scholar 

  15. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.Cancer Res 53:4004–4009, 1993.

    PubMed  CAS  Google Scholar 

  16. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-lM potassium oxonate (S-l) against human colon carcinoma orthotopically implanted into nude rats.Cancer Res 56:2602–2606, 1996.

    PubMed  CAS  Google Scholar 

  17. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T: Antitumor activity and low intestinal toxicity of S-l, a new formulation of oral tegafur, in experimental tumor models in rats.Cancer Chemother Pharmacol 39:205–211, 1997.

    Article  PubMed  CAS  Google Scholar 

  18. Yoshisue K, Hironaga K, Yamaguchi S, Yamamoto A, Nagayama S, Kawaguchi Y: Reduction of 5-fluo-rouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.Cancer Chemother Pharmacol 46:51–56, 2000.

    Article  PubMed  CAS  Google Scholar 

  19. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagashi S, Nakao I: Phase I study of S-l.Jpn J Cancer Chemother 24:2253–2264, 1997 (in Japanese with English abstract).

    CAS  Google Scholar 

  20. World Health Organization: WHO handbook for reporting results of cancer treatment WHO offset Publ. No.48. Geneva, World health organization, 1979.

    Google Scholar 

  21. Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy.JJpn Soc Cancer Ther 28:101–130, 1993.

    Google Scholar 

  22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations.J Am Stat Assoc 53:457–481, 1958.

    Article  Google Scholar 

  23. Arellano M, Malet-Martino M, Martino R, Gires P: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.Br J Cancer 77:79–86, 1988.

    Google Scholar 

  24. Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetatic acid and α-fluoro-β-alanine.Acta Neuropathol 81:66–73, 1990.

    Article  PubMed  CAS  Google Scholar 

  25. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Part YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, Levin B: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.J Clin Oncol 12:2296–2300, 1994.

    PubMed  CAS  Google Scholar 

  26. Villalon AH, De Guzman LM, Samson MC, Guancia AA, Fernando GY, Romana IB: A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at the Philippines general hospital.Oncology 54 (Suppl. 1):2–6, 1997.

    Article  PubMed  CAS  Google Scholar 

  27. Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J: Comparison of 5-Fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus Nl-(2’-tetrahydrofuryl)-5-fluorouracil.Clin Cancer Res 4:2085–2088, 1998.

    PubMed  CAS  Google Scholar 

  28. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Shirasaka T: Pharmacokinetic study of S-l, a novel oral fluorouracil antitumor drug.Clin Cancer Res 5:2002–2005, 1999.

    Google Scholar 

  29. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-l (IM tega-fur-0.4M gimestat-lM otastat potassium) in advanced gastric cancer patients.Eur J Cancer 34:1715–1720, 1998.

    Article  PubMed  CAS  Google Scholar 

  30. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol 17:485–493, 1999.

    PubMed  CAS  Google Scholar 

  31. Blum JL, Dieras V, Russo PML, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.Cancer 92:1759–1768, 2001.

    Article  PubMed  CAS  Google Scholar 

  32. Smorenburg CH, Sparreboom A, Bontenbal M, Ver-weij J: Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.Eur J Cancer 37:2310–2323, 2001.

    Article  PubMed  CAS  Google Scholar 

  33. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishit-suka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.Cancer Res 58:685–690, 1998.

    PubMed  CAS  Google Scholar 

  34. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemohtherapy.J Clin Oncol 15:110–115, 1997.

    PubMed  CAS  Google Scholar 

  35. Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluo-rouracil.Proc Natl Acad Sei USA 90:11064–11068, 1993

    Article  CAS  Google Scholar 

  36. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.J Clin Oncol 14:3085–3096, 1996.

    PubMed  CAS  Google Scholar 

  37. Rivera E, Sutton L, Colwell B, Graham M, Frye D, Somerville M, Conklin HS, McGuirt C, Levin J, Horto-bagyi GN: Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.J Clin Oncol 20:987–993, 2002.

    Article  PubMed  CAS  Google Scholar 

  38. Diasio RB: An evolving role for oral fluoropyrimidine drugs.J Clin Oncol 20:894–896, 2002.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Toshiaki Saeki.

About this article

Cite this article

Saeki, T., Takashima, S., Sano, M. et al. A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working group. Breast Cancer 11, 194–202 (2004). https://doi.org/10.1007/BF02968301

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968301

Key words

Navigation